Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Nature ; 566(7743): E6, 2019 02.
Article in English | MEDLINE | ID: mdl-30670873

ABSTRACT

In this Article, the top label in Fig. 5d should read 'DISH 3/16' instead of 'DISH 3/17'. This error has been corrected online.

2.
Nature ; 563(7733): 639-645, 2018 11.
Article in English | MEDLINE | ID: mdl-30464338

ABSTRACT

The diversity and complexity of the human brain are widely assumed to be encoded within a constant genome. Somatic gene recombination, which changes germline DNA sequences to increase molecular diversity, could theoretically alter this code but has not been documented in the brain, to our knowledge. Here we describe recombination of the Alzheimer's disease-related gene APP, which encodes amyloid precursor protein, in human neurons, occurring mosaically as thousands of variant 'genomic cDNAs' (gencDNAs). gencDNAs lacked introns and ranged from full-length cDNA copies of expressed, brain-specific RNA splice variants to myriad smaller forms that contained intra-exonic junctions, insertions, deletions, and/or single nucleotide variations. DNA in situ hybridization identified gencDNAs within single neurons that were distinct from wild-type loci and absent from non-neuronal cells. Mechanistic studies supported neuronal 'retro-insertion' of RNA to produce gencDNAs; this process involved transcription, DNA breaks, reverse transcriptase activity, and age. Neurons from individuals with sporadic Alzheimer's disease showed increased gencDNA diversity, including eleven mutations known to be associated with familial Alzheimer's disease that were absent from healthy neurons. Neuronal gene recombination may allow 'recording' of neural activity for selective 'playback' of preferred gene variants whose expression bypasses splicing; this has implications for cellular diversity, learning and memory, plasticity, and diseases of the human brain.


Subject(s)
Alzheimer Disease/genetics , Alzheimer Disease/pathology , Amyloid beta-Protein Precursor/genetics , Genetic Variation/genetics , Neurons/cytology , Neurons/pathology , Recombination, Genetic , Alternative Splicing/genetics , Animals , DNA, Complementary/analysis , DNA, Complementary/genetics , DNA-Directed DNA Polymerase/metabolism , Exons/genetics , Female , Humans , Introns/genetics , Male , Mice , Mice, Transgenic , Neurons/metabolism , Organ Specificity , Point Mutation/genetics , RNA, Messenger/analysis , RNA, Messenger/genetics , Sequence Analysis, DNA , Sequence Deletion/genetics
3.
Proc Natl Acad Sci U S A ; 118(47)2021 11 23.
Article in English | MEDLINE | ID: mdl-34795060

ABSTRACT

Down syndrome (DS), trisomy of human chromosome 21 (HSA21), is characterized by lifelong cognitive impairments and the development of the neuropathological hallmarks of Alzheimer's disease (AD). The cellular and molecular modifications responsible for these effects are not understood. Here we performed single-nucleus RNA sequencing (snRNA-seq) employing both short- (Illumina) and long-read (Pacific Biosciences) sequencing technologies on a total of 29 DS and non-DS control prefrontal cortex samples. In DS, the ratio of inhibitory-to-excitatory neurons was significantly increased, which was not observed in previous reports examining sporadic AD. DS microglial transcriptomes displayed AD-related aging and activation signatures in advance of AD neuropathology, with increased microglial expression of C1q complement genes (associated with dendritic pruning) and the HSA21 transcription factor gene RUNX1 Long-read sequencing detected vast RNA isoform diversity within and among specific cell types, including numerous sequences that differed between DS and control brains. Notably, over 8,000 genes produced RNAs containing intra-exonic junctions, including amyloid precursor protein (APP) that had previously been associated with somatic gene recombination. These and related results illuminate large-scale cellular and transcriptomic alterations as features of the aging DS brain.


Subject(s)
Aging/physiology , Down Syndrome/metabolism , RNA Isoforms/metabolism , Alzheimer Disease/metabolism , Amyloid beta-Protein Precursor/metabolism , Brain/metabolism , Chromosomes, Human, Pair 21 , Core Binding Factor Alpha 2 Subunit/metabolism , Down Syndrome/genetics , Gene Expression , Humans , Microglia , RNA/metabolism , Sequence Analysis, RNA , Up-Regulation
5.
Nucleic Acids Res ; 42(8): 4972-84, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24561807

ABSTRACT

In quiescent fibroblasts, the expression levels of cytosolic enzymes for thymidine triphosphate (dTTP) synthesis are down-regulated, causing a marked reduction in the dTTP pool. In this study, we provide evidence that mitochondrial thymidylate synthesis via thymidine kinase 2 (TK2) is a limiting factor for the repair of ultraviolet (UV) damage in the nuclear compartment in quiescent fibroblasts. We found that TK2 deficiency causes secondary DNA double-strand breaks formation in the nuclear genome of quiescent cells at the late stage of recovery from UV damage. Despite slower repair of quiescent fibroblast deficient in TK2, DNA damage signals eventually disappeared, and these cells were capable of re-entering the S phase after serum stimulation. However, these cells displayed severe genome stress as revealed by the dramatic increase in 53BP1 nuclear body in the G1 phase of the successive cell cycle. Here, we conclude that mitochondrial thymidylate synthesis via TK2 plays a role in facilitating the quality repair of UV damage for the maintenance of genome integrity in the cells that are temporarily arrested in the quiescent state.


Subject(s)
Cell Nucleus/genetics , DNA Repair , Mitochondria/enzymology , Stress, Physiological/genetics , Thymidine Kinase/physiology , Thymine Nucleotides/biosynthesis , Cell Cycle , Cell Line , DNA Breaks, Double-Stranded , DNA Damage , Deoxyribonucleotides/metabolism , Genome , Humans , Intracellular Signaling Peptides and Proteins/analysis , Thymidine Kinase/metabolism , Tumor Suppressor p53-Binding Protein 1 , Ultraviolet Rays
6.
J Exp Neurosci ; 13: 1179069519849669, 2019.
Article in English | MEDLINE | ID: mdl-31205422

ABSTRACT

A first example of somatic gene recombination (SGR) within the human brain was recently reported, involving the well-known Alzheimer's disease (AD)-related gene amyloid precursor protein (APP). SGR was characterized by the creation of APP genomic complementary DNA (gencDNA) sequences that were identified in prefrontal cortical neurons from both normal and sporadic Alzheimer's disease (SAD) brains. Notably, SGR in SAD appeared to become dysregulated, producing many more numbers and forms of APP gencDNAs, including 11 single-nucleotide variations (SNVs) that are considered pathogenic APP mutations when they occur in families, yet are present mosaically among SAD neurons. APP gene transcription, reverse transcriptase (RT) activity, and DNA strand-breaks were shown to be three key factors required for APP gencDNA production. Many mechanistic details remain to be determined, particularly how APP gencDNAs are involved in AD initiation and progression. The possibility of reducing disease-related SGR through the use of RT inhibitors that are already FDA-approved for HIV and Hepatitis B treatment represents both a testable hypothesis for AD clinical trials and a genuine therapeutic option, where none currently exists, for AD patients.

7.
Cell Cycle ; 14(3): 354-63, 2015.
Article in English | MEDLINE | ID: mdl-25659034

ABSTRACT

Cellular supply of deoxynucleoside triphosphates (dNTPs) is crucial for DNA replication and repair. In this study, we investigated the role of CMP/UMP kinase (CMPK), an enzyme catalyzes CDP formation, in DNA repair. Knockdown of CMPK delays DNA repair during recovery from UV damage in serum-deprived cells but not in the cells without serum deprivation. Exogenous supply of cytidine or deoxycytidine facilitates DNA repair dependent on CMPK in serum-deprived cells, suggesting that the synthesis of dCDP or CDP determines the rate of repair. However, CMPK knockdown does not affect the steady state level of dCTP in serum-deprived cells. We then found the localization of CMPK at DNA damage sites and its complex formation with Tip60 and ribonucleotide reductase. Our analysis demonstrated that the N-terminal 32-amino-acid of CMPK is required for its recruitment to DNA damage sites in a Tip60-dependent manner. Re-expression of wild-type but not N-terminus deleted CMPK restores the efficiency of DNA repair in CMPK knockdown cells. We proposed that site-specific dCDP formation via CMPK provides a means to facilitate DNA repair in serum-deprived cells.


Subject(s)
DNA Repair , Nucleoside-Phosphate Kinase/metabolism , Culture Media, Serum-Free , Cytidine/metabolism , DNA Damage , DNA Repair/radiation effects , Deoxycytosine Nucleotides/metabolism , Gene Knockdown Techniques , HEK293 Cells , HeLa Cells , Humans , MCF-7 Cells , Models, Biological , Multiprotein Complexes/metabolism , Ultraviolet Rays
8.
Cancer Cell ; 22(1): 36-50, 2012 Jul 10.
Article in English | MEDLINE | ID: mdl-22789537

ABSTRACT

The synthesis of dTDP is unique because there is a requirement for thymidylate kinase (TMPK). All other dNDPs including dUDP are directly produced by ribonucleotide reductase (RNR). We report the binding of TMPK and RNR at sites of DNA damage. In tumor cells, when TMPK function is blocked, dUTP is incorporated during DNA double-strand break (DSB) repair. Disrupting RNR recruitment to damage sites or reducing the expression of the R2 subunit of RNR prevents the impairment of DNA repair by TMPK intervention, indicating that RNR contributes to dUTP incorporation during DSB repair. We identified a cell-permeable nontoxic inhibitor of TMPK that sensitizes tumor cells to doxorubicin in vitro and in vivo, suggesting its potential as a therapeutic option.


Subject(s)
DNA Repair , Deoxyuracil Nucleotides/metabolism , Nucleoside-Phosphate Kinase/metabolism , Animals , Antineoplastic Agents/pharmacology , Cell Line, Tumor , DNA Damage , Doxorubicin/pharmacology , Female , Mice , Mice, Inbred BALB C , Nucleoside-Phosphate Kinase/antagonists & inhibitors , Ribonucleotide Reductases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL